Defitelio launches in Europe


Jazz Pharmaceuticals (JAZZ +3.5%) and its recent acquisition Gentium launch Defitelio (defibrotide) in Germany and Austria.

The rollout will continue in 27 additional European countries in 2014 and 2015.

Defitelio is the first licensed product for severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.

The European Commission approved the product in October.

Consensus Q1 and Q2 estimates are earnings of $1.91 on revenues of $259M and $1.97 on revenues of $276.3M, respectively.

Consensus estimates for 2014 and 2015 are earnings of $8.21 on revenues of $1.14B and $10.16 on revenues of $1.36B, respectively.

574 mutual funds have positions, up from 448 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs